Key Considerations for Maximizing LV and AAV Production in Transient Transfection Workflows

This webcast features: Leisha Kopp, Applications Scientist, Mirus Bio

Recombinant adenoassociated virus (AAV) and lentivirus (LV) are critical components of gene and cell therapies, which show incredible promise for the treatment of disease. Accordingly, the need for large-scale manufacture of safe and effective viral vectors has never been greater. Here, we present:

  • Optimization strategies for AAV and LV generation in both adherent and suspension HEK 293 cells
  • LV and AAV enhancers that further increase functional virus titers over previously optimized conditions
  • How TransIT-VirusGEN® Transfection Reagent and Kits can expand manufacturing capabilities for gene and cell therapies

Just fill out the form below to watch the recorded webcast.



Leave a Reply